2016-04-22-深交所-佛慈制药_2016年第一季度报告正文_8页_211kb

报告摘要

Financial Summary for Lanzhou Fuci Pharmaceutical Co., Ltd. Q1 2016

Key Financial Metrics:
- Revenue: RMB 87.08 million, up 15.32% year-over-year.
- Net Profit: RMB 9.24 million, up 47.90% year-over-year.
- Diluted Earnings Per Share: 0.0181, up 36.09% year-over-year.
- Overall performance showed strong growth in profitability.
Reasons for Changes:
- Revenue increase driven by enhanced marketing and product adjustments.
- Non-recurring items: A net loss of RMB 332,801 from non-recurring events like asset disposals and government grants.
- Operating Cash Flow: RMB 12.41 million, up 70.19% year-over-year, attributed to effective working capital management.
Shareholder Information:
- Top shareholders include Lanzhou Fuci Pharmaceutical Plant (60.09% stake) and several institutional investors, holding between 15% and 2.45%.
- No significant changes in shareholder structure during the period.
Future Outlook:
- Expected profit increase of 10–50% for the first half of 2016, reaching RMB 2.11–2.87 million.
- Reasons cited: Continued revenue growth and strategic investment returns from cash management.